HOME>News & Media
Innovation today, healthier tomorrows

 

For media inquiries, contact us at +44 (0) 20 7821 2840 or email at info@sunovion.eu.



 Date  Title
16 Nov 2016 Sunovion Pharmaceuticals Europe Ltd. and NewBridge Pharmaceuticals Announce Agreement for Distribution of Latuda®▼(lurasidone) in the Gulf Cooperation Council Region
7 June 2016 Sunovion Pharmaceuticals Europe Ltd. and Medicines Optimisation Innovation Centre (MOIC) form a partnership for Mental Health
15 Oct 2015 Sunovion Celebrates Five-Year Anniversary Milestone
17 Mar 2015 All Wales Medicines Strategy Group Recommends Atypical Antipsychotic LATUDA® (lurasidone) as a Treatment Option for Schizophrenia in Adults
13 Oct 2014 Scottish Medicines Consortium Recommends LATUDA® (lurasidone), an Atypical Antipsychotic Agent for Adults with Schizophrenia, as a New Treatment Offering a Combination of Efficacy with Tolerability
21 Aug 2014 Latuda® (lurasidone), a New Atypical Antipsychotic Agent for Adults with Schizophrenia, Now Available in the UK, Offers a Combination of Efficacy with Tolerability
21 Jul 2014 Sunovion Pharmaceuticals Europe Ltd. Announces Data Showing Long-Term Treatment with Latuda® (lurasidone) Was Associated with a Significantly Lower Risk of Metabolic Syndrome Compared with Risperidone
31 Mar 2014 Sunovion Pharmaceuticals Europe Announce the European Marketing Authorisation for Latuda® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
27 Jan 2014 Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
9 Oct 2013 Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone – A New Atypical Antipsychotic treatment for Adults with Schizophrenia
2 Apr 2013 Sunovion Europe Announces New Name
25 Oct 2012 DSPE Regulatory Update: Acceptance of the European Medicines Agency Submission for an Atypical Antipsychotic Agent Lurasidone
18 Mar 2011 DSPE's Support for Japan's Disaster Relief Effort
17 Nov 2009 DSPE is awarded prestigious ‘Investors in People’ Standard

 

If you would like details about Sumitomo Dainippon Pharma's global news please visit Sumitomo Dainippon Pharma News Releases. If you would like details about Sunovion Pharmaceutical Inc.'s news releases, please visit Sunovion Pharmaceutical Inc. News Releases.

 

Home | Contact Us | Site Map | Terms of Use | Privacy and Cookie Policy | About Sumitomo Dainippon Pharma
Sunovion is a trademark of Sumitomo Dainippon Pharma Co., Ltd., Osaka, Japan. © 2016 Sunovion Pharmaceuticals Europe Ltd., All rights reserved.